AlgometRx
AlgometRx is a Washington, DC medical device startup that sells the Nociometer, a device using pupil-dilation analysis to objectively characterize pain type, intensity, and analgesic response for hospitals, pediatric oncology, rheumatology, and pharma clinical-trial sponsors.
- Company typePrivate
- Founded2015
- HeadquartersWashington, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What AlgometRx does
AlgometRx, Inc. is a private medical device startup founded in 2015 and headquartered in Washington, DC, spun out of Children's National Hospital by pediatric anesthesiologist Dr. Julia Finkel. The company addresses the problem that pain is treated empirically through trial-and-error prescribing, which produces poor efficacy, higher costs, side effects, tolerance, and medication abuse. Its mission is to make pain assessment objective and quantitative so clinicians and clinical-trial sponsors can make more informed treatment decisions.
The company's sole commercial product is the Nociometer, a medical device that captures pupil-dilation response to neuroselective stimulation and uses proprietary algorithms to formulate a "nociceptive profile" — a new construct that characterizes pain type and intensity and assesses the pharmacodynamic impact of analgesics. The platform is designed to be applicable to any patient population, including pediatric and non-communicative patients who cannot self-report pain. The device is positioned for two primary use cases: clinical pain management in hospitals and healthcare systems, and as an objective endpoint to speed and sharpen analgesic clinical trials run by pharmaceutical companies.
AlgometRx operates a hardware sales model, targeting enterprise buyers — hospitals, healthcare systems, clinical research organizations, and pharma clinical-trial sponsors — via direct field sales. Pricing is not publicly disclosed and is likely negotiated on a per-institution basis. The company has been funded almost entirely through non-dilutive sources — NIH SBIR Phase 1 grants from NCI and NIAMS, an $8.1M ARPA-H Sprint for Women's Health award (Nov 2024), and participation in accelerators including MedTech Innovator — rather than venture or private equity capital. It has won validation through the FDA Innovation Challenge (2019), Washington Business Journal Fire Awards (2021), and recognition in Nature Outlook (2024), but has not disclosed commercial product revenue.
AlgometRx firmographics
Firmographics- Name
- AlgometRx
- Legal name
- AlgometRx, Inc.
- Website
- https://algometrx.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- AlgometRx is a Washington, DC medical device startup that sells the Nociometer, a device using pupil-dilation analysis to objectively characterize pain type, intensity, and analgesic response for hospitals, pediatric oncology, rheumatology, and pharma clinical-trial sponsors.
- Ownership category
- akta.pro rank
AlgometRx industry classification
Industry- Product category
- Pain Management Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices) (CRACAQAK)
Keywords
Where AlgometRx is headquartered
LocationHeadquarters
- HQ city
- Washington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AlgometRx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Nociometer Device Sales: Sale of the Nociometer medical device to healthcare systems, hospitals, and clinical settings. The platform technology can be applied to any population, enabling broad market applicability.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
AlgometRx product offering
Product offeringCore offering
AlgometRx develops and sells the Nociometer®, a medical device platform that analyzes pupil dilation in response to neuroselective stimulation to formulate a nociceptive profile. The device objectively characterizes pain type and intensity and assesses the pharmacodynamic impact of analgesics, enabling personalized treatment decisions, objective pain assessment in non-communicating patients, and more efficient clinical trials for analgesics. The product is sold to healthcare providers, hospitals, clinical research organizations, and pharmaceutical companies developing pain therapeutics.
Product overview
AlgometRx is a medical device startup spun out from Children's National Hospital in 2015, founded by pediatric anesthesiologist Dr. Julia Finkel. The company offers the Nociometer® platform as its core product—a novel medical device that analyzes pupil dilation in response to neuroselective stimulation to formulate nociceptive profiles. This technology enables objective assessment of pain type and intensity, evaluation of analgesic pharmacodynamics, and supports personalized medicine, treatment decision-making, and drug development applications. The platform is designed for application across any patient population.
Differentiator
Problem solved
Functional benefit
Products and services
- Nociometer® Platform A medical device platform that analyzes pupil dilation in response to neuroselective stimulation to formulate nociceptive profiles. The Nociometer enables objective characterization of pain type and intensity, assessment of the pharmacodynamic impact of analgesics, and personalized pain treatment. It can be applied across any patient population, including pediatric and other non-communicating patients, and supports analgesic clinical trial endpoints for pharmaceutical sponsors.
Quantifiable outcome
- Reduced healthcare costs through elimination of trial-and-error prescribing
- +1 more outcomes
Companies that use AlgometRx
Customer profileSegments4 records
Ideal customer profiles3 records
AlgometRx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
AlgometRx partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Children's National Research InstitutecoreAlgometRx is part of a collaboration led by Children's National Research Institute that was selected by ARPA-H for the Sprint for Women's Health initiative. The project received $8.1 million in funding through the launchpad track for later-stage development health solutions.
- Johns HopkinscoreCollaborating partner in the $8.1 million ARPA-H Sprint for Women's Health award with Children's National Research Institute leading the initiative.
- MedTech InnovatorminorSelected to participate in MedTech Innovator Pediatric Accelerator, providing mentorship, networking, and exposure to potential partners and investors in the medtech ecosystem.
- Children's National HospitalcoreAlgometRx was spun out from Children's National Hospital in 2015 by pediatric anesthesiologist Dr. Julia Finkel, maintaining ongoing research and partnership relationships.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
AlgometRx competitors and assessment
Company assessmentDirect peers
- Medasense Biometrics: Medasense develops the PMD-200 and NOL (Nociception Level) index, an objective pain/nociception monitor using physiological signals in surgical and perioperative settings. It is the most direct competitor to AlgometRx's Nociometer in the objective pain measurement category.
- MDoloris Medical Systems: MDoloris markets the Analgesia Nociception Index (ANI), an objective nociception/analgesia monitor for surgical and ICU use. It directly competes with AlgometRx's positioning of objective, quantitative pain measurement.
Broad incumbents
- SPR Therapeutics: SPR Therapeutics commercializes peripheral nerve stimulation systems (e.g., SPRINT) for chronic and acute pain. While it addresses pain differently (therapy vs. assessment), it competes for the same hospital pain management budget.
- Saluda Medical: Saluda Medical develops closed-loop spinal cord stimulation systems for chronic pain. It is a broader incumbent in the interventional pain management space that may integrate or compete with objective pain assessment.
- Hinge Health: Hinge Health is a leading digital musculoskeletal and chronic pain platform for employers and payers. While not a hardware device, it represents a major alternative care pathway that could displace or complement objective in-clinic pain assessment.
- Sword Health: Sword Health provides AI-driven digital physical therapy and MSK pain management. Like Hinge Health, it represents an alternative, scalable pain care paradigm competing for the same clinical and payer relationships.
Emerging players
- AppliedVR: AppliedVR develops FDA-authorized virtual reality therapeutics for chronic pain. It overlaps with AlgometRx's pain management positioning via a different modality (digital therapeutic vs. objective measurement) and could become a complementary or competing solution in pain clinics.
- Akili Interactive: Akili Interactive develops FDA-cleared digital therapeutics for cognitive and neurological conditions. It is comparable to AlgometRx as a small-cap, clinically validated digital/medical technology company pursuing novel regulatory pathways.
Others
- HeartFlow: HeartFlow commercializes AI-powered, non-invasive cardiac diagnostics from imaging. Although in a different therapeutic area, it shares AlgometRx's profile of using computer vision and AI on physiological signals to produce objective clinical assessments.
- Paige.AI: Paige applies AI/computer vision to pathology for cancer diagnosis. Similar to AlgometRx, it demonstrates the regulatory and commercial viability of AI-enabled medical imaging diagnostics, providing a useful comparable for technology and adoption path.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
AlgometRx social profiles
Digital presenceAlgometRx financial estimates
Financial estimateRevenue estimate
Valuation estimate
AlgometRx leadership team
Management profileNumber of profiles
Profiles3 records
AlgometRx funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AlgometRx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AlgometRx
What does AlgometRx do?
AlgometRx develops and sells the Nociometer®, a medical device platform that analyzes pupil dilation in response to neuroselective stimulation to formulate a nociceptive profile. The device objectively characterizes pain type and intensity and assesses the pharmacodynamic impact of analgesics, enabling personalized treatment decisions, objective pain assessment in non-communicating patients, and more efficient clinical trials for analgesics. The product is sold to healthcare providers, hospitals, clinical research organizations, and pharmaceutical companies developing pain therapeutics.
Is AlgometRx a public or private company?
AlgometRx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AlgometRx founded?
AlgometRx was founded in 2015. It employs 1 to 10 people.
Where is AlgometRx based?
AlgometRx is headquartered in Washington, United States, in the North America region.
How does AlgometRx make money?
One revenue line is on record: nociometer Device Sales.
Who are AlgometRx's main competitors?
Direct peers on record are Medasense Biometrics and MDoloris Medical Systems. Broad incumbents are SPR Therapeutics, Saluda Medical, Hinge Health and Sword Health. Emerging players are AppliedVR and Akili Interactive. Others are HeartFlow and Paige.AI.
Does AlgometRx have an API?
No public API is recorded for AlgometRx.
What industry is AlgometRx in?
AlgometRx's product category is Pain Management Medical Devices. Its primary akta.pro industry code is CRACAQAK, Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices). Its NAICS code is 334510 and its SIC code is 3845.